This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riesbeck, K. Articles by Lechler, R. I. Search for Related Content PubMed PubMed Citation Articles by Riesbeck, K. Articles by Lechler, R. I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Circulation. 1998;98:2744-2752.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Expression of Hirudin Fusion Proteins in Mammalian Cells

A Strategy for Prevention of Intravascular Thrombosis

Kristian Riesbeck, PhD; Daxin Chen, PhD; Geoffrey Kemball-Cook, PhD; John H. McVey, PhD; Andrew J. T. George, PhD; Edward G. D. Tuddenham, PhD; Anthony Dorling, PhD; Robert I. Lechler, PhD

From the Xenotransplantation Research Group, Department of Immunology (K.R., D.C., A.J.T.G., A.D., R.I.L.) and MRC Clinical Sciences Centre Haemostasis Research Group (G.K.-C., J.H.M., E.G.D.T.), Imperial College of Science Technology and Medicine, Hammersmith Hospital, London, UK. Dr Riesbeck is presently at the Department of Medical Microbiology, University Hospital, Lund University, Malmo, Sweden.

Background—Intravascular thrombosis occurs in disorders of diverse pathogeneses, including allograft and xenograft rejection. In this in vitro study, we describe an approach for tethering the specific thrombin inhibitor hirudin to plasma membranes as part of a genetic strategy for regulating intravascular coagulation.

Methods and Results—An HLA class I leader sequence was fused with hirudin linked to domains 3 and 4 of human CD4 and intracytoplasmic sequence from either CD4 or human P-selectin. The constructs were transfected into mouse fibroblasts, Chinese hamster ovary (CHO)-K1 cells, immortalized porcine endothelial cells (IPECs), and a pituitary secretory cell line (D16/16). Thrombin binding to the hirudin fusion proteins expressed on fibroblasts and CHO-K1 cells could be blocked by an anti-hirudin monoclonal antibody and by pretreatment of thrombin with either the synthetic tripeptide thrombin inhibitor PPACK or native hirudin. Hirudin expression significantly modified the procoagulant phenotype of IPECs in human plasma, leading to prolongation of clotting times. Hirudin-CD4–P-selectin fusion proteins accumulated in adrenocorticotropic hormone–containing granules in D16/16 cells, with no cell surface expression except on activation with phorbol ester, when hirudin relocated to the outer membrane.

Conclusions—Hirudin fusion proteins were expressed on mammalian cells, where they reduced local thrombin levels and inhibited fibrin formation. Regulated expression was achieved on activated cells by use of the cytoplasmic sequence from P-selectin. In vivo, these fusion proteins may prove useful transgenic or gene therapy agents for preventing intravascular thrombosis.

Key Words: anticoagulants • coagulation • transplantation • thrombosis

This article has been cited by other articles:

				D. Chen, K. Giannopoulos, P. G. Shiels, Z. Webster, J. H. McVey, G. Kemball-Cook, E. Tuddenham, M. Moore, R. Lechler, and A. Dorling Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium Blood, September 1, 2004; 104(5): 1344 - 1349. [Abstract] [Full Text] [PDF]

				M D Dooldeniya and A N Warrens Xenotransplantation: where are we today? J R Soc Med, March 1, 2003; 96(3): 111 - 117. [Full Text] [PDF]